Ongoing studies are exploring novel therapies targeting plasma cell, B‐cell lineage, and other pathways, for instance, ongoing clinical trials evaluating daratumumab hyaluronidase NCT05004259, isatuximab NCT04661033, BTK inhibitors, and other agents in adults with warm AIHA to advance current treatment. Here, BTK is linked to autoimmune hemolytic anemia.